MT
MTVA.US MetaVia Inc.
- Market cap
- USD 8.56M
- P/E
- -
- P/B
- 1.26x
- ROE
- -761.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MTVA.US undervalued?
Graham numberThe Graham number of MetaVia Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MetaVia Inc. fundamental analysis
No fundamental analysis for MetaVia Inc. yet.
MetaVia Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; …
Full company profileMetaVia Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MetaVia Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | -67.0K | -72.0K | -28.0K | -7.00K | -24.0K | -19.0K | - |
| Operating Income | -14.7M | -33.1M | -15.5M | -20.2M | -29.7M | -15.3M | -19.6M | -15.9M | -28.8M | -13.7M | -18.8M |
| EBITDA | -14.7M | -33.1M | -15.5M | -20.2M | -29.7M | -15.2M | -11.8M | -12.5M | -27.6M | -13.0M | -18.5M |
| Net Income | -14.6M | -33.4M | -15.5M | -21.3M | -29.7M | -15.3M | -14.0M | -12.5M | -27.6M | -13.0M | -18.3M |
| EPS | -104,186 | -212,834 | -74,301 | -10,769 | -4,831 | -1,743 | -478 | -27 | -39 | -7.35 | -2.72 |
| Balance Sheet | |||||||||||
| Total Assets | 24.8M | 19.0M | 3.82M | 14.5M | 11.0M | 16.8M | 33.5M | 22.8M | 16.3M | 11.1M | 9.55M |
| Total Liabilities | 4.12M | 15.1M | 17.1M | 2.18M | 3.77M | 2.20M | 11.8M | 6.10M | 8.33M | 5.79M | 7.14M |
| Shareholders' Equity | 20.6M | 3.94M | -13.3M | 12.3M | 7.20M | 14.6M | 21.8M | 16.7M | 7.93M | 5.33M | 2.41M |
| Cash & Short-term Investments | 24.0M | 18.5M | 2.85M | 13.9M | 10.1M | 16.4M | 33.4M | 22.4M | 16.0M | 10.3M | 8.78M |
| Total Debt | - | 10.0M | 9.58M | 116K | 94.0K | 71.0K | - | 203K | 136K | 210K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.0M | -26.9M | -14.5M | -7.04M | -10.8M | -15.1M | -11.7M | -10.8M | -24.7M | -15.7M | -15.7M |
| Capital Expenditure | 0.00 | 0.00 | 3.00K | 214K | 4.00K | 3.00K | 0.00 | 50.0K | 8.00K | 2.00K | 0.00 |
| Free Cash Flow | -11.0M | -26.9M | -14.5M | -7.25M | -10.8M | -15.1M | -11.7M | -10.8M | -24.7M | -15.7M | -15.7M |
| Ratios | |||||||||||
| ROE | -70.7% | -847.9% | - | -173.4% | -412.0% | -104.7% | -64.2% | -74.7% | -347.9% | -243.3% | -761.1% |
| ROA | -58.9% | -175.7% | -406.5% | -147.3% | -270.6% | -91.0% | -41.7% | -54.7% | -169.7% | -116.6% | -192.1% |
| Debt to Equity | - | 2.55x | - | 0.01x | 0.01x | 0.00x | - | 0.01x | 0.02x | 0.04x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
MetaVia Inc. dividends
MetaVia Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:11 on Dec 5, 2025.
Who owns MetaVia Inc.
- Insiders 29.41%
- Institutions 14.25%
- Public & others 56.33%
- Shares outstanding 6.59M
- Free float 4.80M
Top funds holding MTVA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 20.2K | 0.31% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 6.79K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 976.00 | 0.01% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 184.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding MTVA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 124K | 1.88% | +1,033.48% | Jun 2026 |
| Citadel Advisors Llc | 61.2K | 0.93% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 29.9K | 0.45% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 21.3K | 0.32% | -36.63% | Jun 2026 |
| UBS Group AG | 12.9K | 0.20% | +1,294,700.00% | Jun 2026 |
| Scientech Research LLC | 12.0K | 0.18% | 0.00% | Jun 2026 |
| Aries Wealth Management | 10.0K | 0.15% | 0.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 8.92K | 0.14% | +301.40% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 6.94K | 0.11% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 2.22K | 0.03% | -14.57% | Jun 2026 |
| SBI Securities Co Ltd | 270.00 | 0.00% | +31.71% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 10.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.00 | 0.00% | -98.54% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 3.00 | 0.00% | 0.00% | Jun 2026 |
| International Assets Investment Management, LLC | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Brown Brothers Harriman & Co | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 2.00 | 0.00% | 0.00% | Jun 2026 |
MetaVia Inc. company profile
- Company name
- MetaVia Inc.
- Ticker
- MTVA.US
- Exchange
- USA Stocks
- Listed since
- Aug 5, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 545 Concord Avenue, Cambridge, MA, United States, 02138
- Phone
- 857 702 9600
- Website
- metaviatx.com
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MetaVia Inc. management
6- Mr. Hyung Heon KimCEO, President & Director · born 1977
- Mr. Marshall H. WoodworthChief Financial Officer · born 1958
- Dr. Mi-Kyung KimChief Scientific Officer
- Mr. Robert HomolkaSenior Vice President of Clinical Operations
- Mr. Michael C. PineSenior Vice President of Business Development Advisor · born 1977
- Dr. Sarah Kaplan Browne M.D.Chief Medical Officer